IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 11376304 B1

PDFFull Text
Date of Patent:
Jul. 05, 2022

Filed:

Aug. 17, 2020

Methods and compositions for the prevention and treatment of disease

Applicant:

Stealth Biotherapeutics Inc., Needham, MA (US);

Inventor:

D. Travis Wilson, Newton, MA (US);

Assignee:

STEALTH BIOTHERAPEUTICS INC., Needham, MA (US);

Attorney:

Foley & Lardner LLP

Primary Examiner:

Sudhakar Katakam

Assistant Examiner:

Zachary J Miknis

Int. Cl.
CPC ...
A61K 38/07 (2006.01); A61K 45/06 (2006.01); A61K 31/192 (2006.01); A61K 31/165 (2006.01); A61P 27/02 (2006.01); A61P 13/12 (2006.01); A61K 38/18 (2006.01); A61K 38/13 (2006.01); A61K 38/06 (2006.01); A61K 31/727 (2006.01); A61K 31/737 (2006.01); A61P 7/06 (2006.01); A61P 9/12 (2006.01); A61P 29/00 (2006.01);
U.S. Cl.
CPC ...
A61K 38/07 (2013.01); A61K 31/165 (2013.01); A61K 31/192 (2013.01); A61K 31/727 (2013.01); A61K 31/737 (2013.01); A61K 38/06 (2013.01); A61K 38/13 (2013.01); A61K 38/1875 (2013.01); A61K 45/06 (2013.01); A61P 7/06 (2018.01); A61P 9/12 (2018.01); A61P 13/12 (2018.01); A61P 27/02 (2018.01); A61P 29/00 (2018.01);
Abstract

The present technology is directed to compositions and methods for preventing, ameliorating, or reducing the severity of one or more signs, or symptoms associated with a reduction of function, decreased expression level of, and/or deficiency in one or more of COL4A3, COL4A4 and COL4A5 genes. Also disclosed herein are methods of preventing or treating Alport Syndrome in a mammalian subject, reducing risk factors associated with Alport Syndrome, and/or reducing the likelihood or severity of Alport Syndrome. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide.

Find Patent Forward Citations

Loading…